248 participants
A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2018-06-12
- Start Date:
- 2015-03-31
- Completion:
- 2017-02-28
Conditions
- Cystic Fibrosis
Interventions
- DRUG